Changes in Body Composition Under Ustekinumab in PsA

TerminatedOBSERVATIONAL
Enrollment

3

Participants

Timeline

Start Date

March 11, 2019

Primary Completion Date

July 11, 2021

Study Completion Date

July 11, 2021

Conditions
Psoriatic Arthritis
Interventions
PROCEDURE

Bone mineral density (BMD)

"The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body)."

Trial Locations (1)

Unknown

Hôpital Roger Salengro, CHU, Lille

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Janssen Pharmaceuticals

INDUSTRY

lead

University Hospital, Lille

OTHER

NCT03823924 - Changes in Body Composition Under Ustekinumab in PsA | Biotech Hunter | Biotech Hunter